Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.
Weihao ChenJingtao HuangYeqian ZhaoLuo HuangZhiyang YuanMiner GuXiaojun XuJimin ShiYi LuoJian YuXiaoyu LaiLizhen LiuHuarui FuChenhui BaoXin HuangZhongzheng ZhengHe HuangXiaoxia HuYanmin ZhaoPublished in: Journal of translational medicine (2024)
ClinicalTrials.gov identifier: NCT06000306. Registered 17 August 2023 -Retrospectively registered ( https://clinicaltrials.gov/study/NCT06000306?term=NCT06000306&rank=1 ).